Latest News

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

As the 2nd International Glaucoma Symposium approaches in Mainz, Germany, Stephan Schulz highlights how the program bridges everyday clinical needs with the latest advances in AI, imaging, and surgery.

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).